Lysosomes and lysosomal hydrolases, including the cathepsins, have been shown to change their properties with aging brain a long time ago, although their function was not really understood. The first biochemical and clinical studies were followed by a major expansion in the last 20 years with the development of animal disease models and new approaches leading to a major advancement of understanding of the role of physiological and degenerative processes in the brain at the molecular level. This includes the understanding of the major role of autophagy and the cathepsins in a number of diseases, including its critical role in the neuronal ceroid lipofuscinosis. Similarly, cathepsins and some other lysosomal proteases were shown to have important roles in processing and/or degradation of several important neuronal proteins, thereby having either neuroprotective or harmful roles. In this review, we discuss lysosomal cathepsins and their regulation with the focus on cysteine cathepsins and their endogenous inhibitors, as well as their role in several neurodegenerative diseases.
Introduction
The discovery of the lysosome by Christian de Duve and colleagues was a major breakthrough in the understanding of intracellular protein degradation processes (de Duve et al., 1955) . These single membrane cytoplasmic organelles with an acidic pH of about 3.8-5.0 contain over 50 acid hydrolases including the cathepsins. The finding that these enzymes degrade numerous biological macromolecules suggested that the lysosomes, also termed "suicide bags" by de Duve, are mainly responsible for their non-specific intracellular degradation. Lysosomes and related organelles, were then discovered in all eukaryotic cells and were found to be involved in the digestion of extracellular material taken-up by endocytosis and of intracellular material segregated by autophagy. Among the lysosomal hydrolases a special role has proteases that are responsible for protein breakdown (de Duve, 1983 (de Duve, , 2005 Turk and Turk, 2009) . With the discovery of the ubiquitin-proteasome system responsible for rapid non-lysosomal degradation of proteins in the cytosol (Ciechanover, 2012) it became clear that there are two major systems for intracellular protein degradation: the lysosome-autophagy system (Cuervo, 2004; Orenstein and Cuervo, 2010) and the ubiquitin-proteasome system (Ciechanover, 2012) .
It is now well established that through proteolytic processing and/or degradation the endolysosomal system is involved in numerous cellular processes responsible for cellular homeostasis and differentiation (Appelqvist et al., 2013; Turk and Turk, 2009 ). While random protein degradation plays a crucial role in general protein turnover, limited proteolysis can alter protein biological activity and its structural integrity which results in transformed physiological function of the processed substrate. Lysosomal proteases, in particular the cathepsins, have thus important functions in immune response including antigen processing and presentation, processing and activation of various proteins and hormones, lysosomal death pathway, autophagy, aging and other processes. However, proteases catalyze irreversible cleavage of peptide bonds. Therefore, their activities must be strictly regulated. These can be achieved in vivo by regulating their gene expression, activation of zymogens, the accessibility of the susceptible peptide bond in the substrates, by action of their endogenous inhibitors, by their compartmentalizaton, post-translational modifications, or combination of all these factors (López-Otín and Bond, 2008; Neurath, 1999) .
Any dysregulation in the protease expressions and/or their proteolytic activities disrupts cellular homeostasis. It appears that multiple mechanisms participate in various degrees of lysosomal permeabilization which result in release of lysosomal enzymes into the cytosol. The amount of potentially hazardous proteolytic enzymes, mostly cathepsins, in the cytosol, might overcome the protective inhibitory effect of endogenous protein inhibitors such as cystatins. Moreover, proteases contribute to many human pathologies such as cancer and metastasis, various neurodegenerative disorders, inflammatory and cardiovascular diseases, and obesity also when secreted into the extracellular milieu.
This review focuses primarily on lysosomal cysteine cathepsins, regulation of their proteolytic activities, and their role in aging and various neurodegenerative disorders.
Endolysosomal proteases
The name cathepsin was introduced in the first half of the 20th century and is now used for the serine proteases cathepsins A and G, the aspartic proteases cathepsins D and E (pepsin family A1A) and cysteine proteases cathepsins B, C, L, F, H, K, O, S, V, X and W (papain family C1A). An additional lysosomal cysteine protease is asparaginyl endopeptidase or legumain (family C13). These enzymes differ in their cellular and tissue distribution, localization and expression profiles, biochemical properties, structural aspect and the regulation of their activity.
Cysteine proteases

Cysteine cathepsins
In humans there are 11 cysteine cathepsins B, C, L, F, H, K, O, S, V, X and W existing at the sequence level, which was confirmed by a bioinformatic analysis of the human genome (Rossi et al., 2004) .
2.1.1.1. Localization and expression. Although all the cathepsins are targeted to endolysomes via the mannose-6-phosphate receptor pathway, or, sometimes, via the mannose-6-phosphate receptorindependent pathway(s) (Von Figura and Hasilik, 1986) , they are not all expressed at the same levels in different tissues (Rossi et al., 2004; Unanue et al., 2016) . Some of the cathepsins such as cathepsins B, H, L, C and O are ubiquitous and highly to moderately expressed in various tissues and cells including in the brain, suggesting that these enzymes play a role in general protein degradation and turnover. Other cathepsins such as cathepsins F, K, S, V, X and W (lymphopain) show more restricted cell and tissue distribution and expression, although all of them except cathepsin W were also found to be involved in CNS biology and/or pathology. Such diverse localization and specific expression of some cysteine cathepsins suggest that they have more specific cellular functions. Recent studies unambiguously show the presence of active cathepsins in other cellular compartments, such as nucleus, cytoplasm and at plasma membrane, which may have a role in neurodegeneration (Cook et al., 2014; Duncan et al., 2008; Goulet et al., 2004; Santos-Rosa et al., 2009 ).
In addition, some specific functions of the cathepsins result from their localization outside the cells. The extracellular localization of cysteine cathepsins is often linked with their increased expression and proteolytic activity. Cathepsins with strong elastolytic and collagenolytic activities, such as cathepsins S, K and V, are mainly responsible for the remodeling of the extracellular matrix (ECM), thereby contributing to normal bone remodeling and hormone processing, but also to various pathologies (Brix et al., 2008; Fonović and Turk, 2014) . The ECM consists of several proteins such as elastins, laminin, collagen and proteoglycans, which are cleaved by the cathepsins (Fonović and Turk, 2014; Lutgens et al., 2007) . These ECM proteins are present in the brain and there is increasing evidence that ECM is implicated in the process of neurodegeneration (Bonneh-Barkay and Wiley, 2009) . Moreover, immune cells are known to be a major source of extracellular cysteine cathepsins in inflammation, including in the brain von Bernhardi et al., 2015; Wendt et al., 2008 Wendt et al., , 2007 . (Musil et al., 1991) and cathepsin L (B) (1icf) (Gunčar et al., 1999) is shown in the ribbon representation of the secondary structure elements (alpha-helix, red; beta-structure, cyan). The side chains of the active-site residues cysteine and histidine are highlighted in a ball-and-stick representation in yellow and blue color, respectively. The "occluding loop" of cathepsin B is highlighted in black.
2.1.1.2. Structure and specificity. The different physiological roles of the cathepsins are, in addition to their localization, partially the consequence of their structural features. The first determined structure of a lysosomal protease was the crystal structure of cathepsin B (Musil et al., 1991) , followed by those of cathepsins L (Fujishima et al., 1997; Gunčar et al., 1999) , K (McGrath et al., 1997) , H , X (Gunčar et al., 2000) , V (Somoza et al., 2000) , C (Turk et al., 2001a) , S (Turkenburg et al., 2002) and F (Somoza et al., 2002) . Structures of cathepsins O and W were so far not determined. All cysteine cathepsins share the same core structure typical for the papain family of proteases and are monomers of about 30 kDa with the exception of the tetrameric cathepsin C, which shows how an additional "exclusion domain" transforms the framework of a papain-like endopeptidase into an oligomeric protease (Turk et al., 2001a,b) . They consist of two domains, which open at the top forming the active site cleft in the middle of which are two catalytic residues, Cys25 and His163 (papain numbering), each originating from a different domain (Fig. 1 ). In accordance with the Schechter and Berger (1967) cleavage site nomenclature (Schechter and Berger, 1967) and structural analysis Turk et al., 1998 ) the active site binding surface consists of substrate binding sites from S3 to S2 and substrate binding areas S4 and, likely, S3 . Structural analysis further revealed that the binding sites with main chain and side chain interactions between the peptidyl substrates and the enzymes are only the S2, S1 and S1 sites, with the S2 site the only one forming a real pocket to accommodate the side-chain of a substrate amino acid residue (Turk et al., , 2001b .
Cysteine cathepsins exhibit broad substrate specificity, preferentially cleaving after basic or hydrophobic amino acid residues, but are unable to cleave the substrates before or after the proline residues. Most of the cysteine cathepsins predominantly exhibit endopeptidase activity, whereas cathepsins B, C, H and X are exopeptidases. However, only cathepsins C and X are strict exopeptidases, whereas cathepsins B and H also exhibit endopeptidase activities (Turk et al., 2012b) . Their exopeptidase activities are the consequence of additional structural features inserted into their active site clefts (Gunčar et al., 2000 Musil et al., 1991; Turk et al., 2001a ) that partially block the access of N-(aminopeptidases) or C-termini (carboxypeptidases) of the substrates. In contrast, in true endopeptidases (cathepsins F, L, K, S and V) the substrates can bind into the active side cleft along the whole length of the two-domain interphase (Turk et al., 2003) . Recently, systematic studies addressing the selectivity of cysteine cathepsins B, L, S and K using proteomic approaches confirmed the broad specificities of these proteases (Biniossek et al., 2011; Schilling and Overall, 2008; Vizovišek et al., 2015) , in agreement with earlier studies using small molecule substrate libraries (Choe et al., 2006) . Collectively, lysosomal cathepsins represent an efficient machinery to degrade proteins to smaller fragments while dipeptidases and other peptidases complete their job.
2.1.1.3. Regulation of protease activity. Cathepsin activities could be very harmful if uncontrolled. In addition to their localization and expression, their action can be controlled in vivo by regulation of their expression, posttranslational modifications, zymogen activation, pH, endogenous and exogenous inhibitors, or a combination of all these factors (López-Otín and Bond, 2008; Turk et al., 2012a,b) .
All lysosomal cathepsins are synthesized as inactive preproenzymes. After the cleavage of the N-terminal signal peptide in the lumen of ER and simultaneous N-linked glycosylation of the proenzyme, called the zymogen, the propeptide assists in proper folding of the zymogen and targeting to the endosomes/lysosomes, as the mannose-6-phosphate moiety, required for receptor binding, usually resides there. In addition, propeptides assure that the zymogens remain inactive until activation that is usually facilitated by mild acidic conditions in the endolysosomal compartments and results in proteolytic removal of the propeptide. Propeptides are namely potent and selective inhibitors of their cognate enzymes at neutral pH in vitro, but with substantially lower potency at acidic pH (Fox et al., 1992; Guay et al., 2000) . Following cleavage, propeptides dissociate from the enzyme, unfold and are likely degraded by other proteases, which can be at least partially attributed to the fact that they show very little homology in their amino acid sequences (Caglič et al., 2007; Ménard et al., 1998; Rozman et al., 1999; Turk et al., 2012b; Wiederanders et al., 2003) . This is supported by the finding that the isolated cathepsin L propeptide unfolds by a pH drop, which parallels a decrease of its affinity towards mature cathepsin L (Jerala et al., 1998) . After proteolytic removal of the propeptide, which can be autocatalytic or mediated by another protease, the proteolytically active mature cathepsins are released.
Major progress in revealing the mechanism of autocatalytic zymogen activation was obtained from the crystal structures of procathepsins B, L and K Podobnik et al., 1997; Sivaraman et al., 1999) . From these structures it is evident that the propeptide chain folds on the surface of the enzyme and runs through the active-site cleft in the opposite direction to that of the substrate, thus blocking substrate access to the already formed active-site of the enzyme. Moreover, these studies indicated that major structural rearrangements previously suggested are highly unlikely. Further hints about the molecular mechanism of cathepsin activation came from the kinetic and mutant studies on cathepsin B, which revealed that autocatalytic activation of cysteine cathepsins is a combination of unimolecular and bimolecular steps. The first step is a unimolecular dissociation of the propeptide from the active site cleft, triggered by lowering the pH, which is followed by bimolecular proteolytic removal of the propeptide in one or several steps in trans. This initiates a sort of chain reaction in which active cathepsin molecules quickly activate the remaining zymogen molecules (Quraishi and Storer, 2001; Rozman et al., 1999; Rozman Pungerčar et al., 2009 ). However, only endopeptidases can be activated autocatalytically, while exopeptidases cathepsin C and cathepsin X require other endopeptidases, such as cathepsins S and L for their activation (Dahl et al., 2001; Nägler et al., 1999 ). Moreover, a major role in the activation of cathepsins, which is likely physiologically relevant, also has negatively charged molecules such as glycosaminoglycans (GAGs) and dextran sulphate (Ishidoh and Kominami, 1995; Mason and Massey, 1992; Rozman et al., 1999) . GAGs were thus found to accelerate activation of cathepsin B including at neutral pH by disrupting the interaction between the propeptide and the mature part in the zymogen, thereby converting the latter into a better substrate (Caglič et al., 2007) . Similar findings were observed also for other cathepsins, such as L and S (Fairhead et al., 2008; Vasiljeva et al., 2005) . In addition, GAGs were shown to accelerate activation of another endolysosomal cysteine protease, legumain (Berven et al., 2013) .
Another factor that was implicated in the regulation of activity of cysteine cathepsins is pH. The cathepsins were thus found to be predominantly active and stable at slightly acidic pH such as found in the endolysosomal vesicles, but relatively unstable at neutral pH such as found in the cytosol and in extracellular milieu (Almeida et al., 2001; Turk et al., 1995a Turk et al., , 1993 Turk et al., , 1994b ). An exception is cathepsin S, which was found to be highly stable even at neutral pH (Kirschke et al., 1989) . For many years it was therefore thought that pH-induced inactivation in combination with oxidative conditions in such milieu are crucial for the control of extralysosomal cathepsin-mediated proteolysis. However, recent studies have demonstrated that the cathepsins are highly active under such conditions for a limited amount of time, which is, however, sufficient to allow for their extralysosomal activity (Jordans et al., 2009; Turk and Turk, 2009 ). Moreover, this was confirmed by identification of their cytosolic substrates such as Bid and other Bcl-2 homologues during apoptosis (Cirman et al., 2004; DrogaMazovec et al., 2008) , as well as identification of their extracellular substrates such as various extracellular matrix proteins (Fonović and Turk, 2014; Olson and Joyce, 2015) , chemokines (Repnik et al., 2015) , transmembrane receptors and adhesion proteins . However, despite the general stability of the cathepsins at the acidic pH, cathepsin L was found to be denatured after prolonged exposure to acidic pH. Moreover, such denatured cathepsin L was found to be cleaved by cathepsin D, which might be of physiological importance for regulation of cathepsin activities by cathepsin D inside the lysosomes .
2.1.1.3.1. Endogenous inhibitors. The major regulators of extralysosomal activities of the cathepsins are, however, their endogenous protein inhibitors among which the best known are cystatins, thyropins and serpins (Abrahamson et al., 2003; Turk et al., 2002 Turk et al., , 1997 Turk and Bode, 1991; Turk et al., 2008 Turk et al., , 2012b . They were found to be very efficient at physiological concentrations even at neutral pH, indicating that their inhibitory potential is not decreased under these conditions (Turk et al., 1994a) .
The cystatins are the largest group of endogenous cathepsin inhibitors and were found both intracellularly and extracellularly. The cystatins are generally potent nonselective inhibitors of cathepsin endopeptidases, but weaker inhibitors of exopeptidases, especially of cathepsin X. They are divided into three inhibitory subfamilies, stefins (type-1 cystatins), cystatins (type-2 cystatins) and kininogens (type-3 cystatins) (Abrahamson et al., 2003; Kordiš and Turk, 2009; Turk et al., 2008 Turk et al., , 2012b . Among them stefin B and cystatin C were found to be widely expressed in numerous tissues, including in the brain, whereas others show more restricted distribution (UniGene database at http://www.ncbi.nlm.nih.gov/ unigene/).
Stefins are single-chain, non-glycosylated proteins without signal sequence and disulphide bridges. They are composed of ∼100 amino acid residues and are primarily intracellular proteins , but were found also in many body fluids (Abrahamson et al., 1986) , where they were even suggested as potential cancer biomarkers (Kos and Lah, 1998) . Stefins A and B, the two founding members of the family, were found in various mammals including humans .
Cystatins are single-chain proteins with ∼115 amino acid residues. They contain signal peptide for secretion and are primarily extracellular inhibitors. There are seven members of the family known in mammals, including cystatin C, salivary cystatins (S, SA and SN), cystatin D, cystatin E/M and cystatin F (leukocystatin). Among the cystatins, cystatin C is the most potent inhibitor of cysteine cathepsins (Turk et al., 2012b) . In addition, cystatin C inhibits legumain, however, the binding site for legumain is different from that for cathepsin binding, allowing simultaneous inhibition of two protease molecules (Alvarez-Fernandez et al., 1999) . Interestingly, cystatin C was found to be degraded by cathepsin D, which may have important physiological consequences (Lenarčič et al., 1991) .
The third inhibitory subfamily are large multifunctional and multidomain plasma glycoproteins, the kininogens. In humans there are two types of kininogens known, high-molecular weight kininogen (HK) and low-molecular weight kininogen (LK). The HK, but not the LK was also localized in neurons, nerve fibers, glial and endothelial cells in rat spinal cord and brain (Li et al., 1999) . Both, HK and LK are composed of three cystatin-like domains, and two of them can simultaneously inhibit two cathepsin molecules, but with different affinities (Turk et al., 1995b .
Thyropins are a much smaller group of protein inhibitors, named after the thyroglobulin type-1 domain, which was found as the first mammalian thyropin identified, the p41 fragment of the MHC class II-associated invariant chain (Bevec et al., 1996; Ogrinc et al., 1993) . Noteworthy, diverse molecules encoded within MHC are expressed in the healthy CNS where they play a critical role in brain development, function and plasticity (Needleman and McAllister, 2012) , further suggesting that the p41 invariant chain fragment might be involved in the regulation of antigen presentation in the CNS. In addition, testican-1, a selective cathepsin L inhibitor, is the only other mammalian thyropin identified to date (Bocock et al., 2003) .
Several mammalian serpins, which inhibit cysteine cathepsins, were also identified. These include endopin 2C from liver and neuroendocrine tissues (Hwang et al., 2005) , squamous cell carcinoma antigen 1 (Schick et al., 1998) and its mouse orthologue SQN-5 (AlKhunaizi et al., 2002) , hurpin (Welss et al., 2003) , and Spi2A (Liu et al., 2003) . While SQN 5, endopin2C and Spi2A inhibit both serine proteases and the cathepsins, hurpin seems to be very selective and only inhibits cathepsin L .
2.1.1.3.2. Mechanism of cathepsin-inhibitor interaction. Determination of crystal structures of chicken cystatin (Bode et al., 1988) and human stefin B-papain complex (Stubbs et al., 1990) were crucial for understanding the interaction between papainlike proteases and cystatins. Both, cystatin and stefin B, consist of a five-turn ␣-helix and a five-stranded antiparallel ␤-pleated sheet, which is twisted and wrapped around the ␣-helix and an appending helix or a strand, respectively (Fig. 2 ). The exposed first ␤-hairpin loop (highly conserved QVVAG region or a similar sequence) is flanked on either side by the amino terminal segment and the second hairpin loop. These loops and the N-terminal form a wedge-shaped edge, which is highly complementary to the active-site of the enzyme, and are responsible for enzyme inhibition. In the stefin B-papain complex both loops interact with the prime subsites adjacent to the enzyme catalytic residue. The NMR structure of chicken cystatin was essentially the same as the crystal structure Engh et al., 1993) . Similarly, the NMR structure of stefin A was in excellent agreement (Stubbs et al., 1990 ) (A) and cystatin C (3gax) (Kolodziejczyk et al., 2010) (B) is shown. The ribbon representation displays colors consistent with the secondary structure elements (alpha-helix, red; beta-structure, cyan).
with that of stefin B (Martin et al., 1995) , confirming previous findings. Interestingly, human cystatin C structure revealed that the inhibitor formed domain-swapped dimers, which may also have explained oligomer formation in the hereditary cystatin C amyloid angiopathy (Janowski et al., 2001 ). Moreover, it was later demonstrated that also stefin B forms tetramers consisting of two-domain swapped dimers. The structure further revealed that tetramerization involves a novel mechanism termed "hand shaking", which is dependent on the trans-to-cis isomerization of the only Pro64 residue, including in cystatin C. The similarities in structure, sequence and oligomerization suggest that tetramerization involving proline isomerization is not limited to stefin B only, but can play a major role in amyloidogenesis (Jenko Kokalj et al., 2007) .
Cathepsin D, the major endolysosomal aspartic protease
Cathepsin D is the major endolysosomal aspartic protease. It is synthesized as a preproenzyme that is, similarly to other endolysosomal proteases, following removal of the signal peptide targeted to endosomes via the mannose-6-phosphate receptor pathway, or via receptor-independent pathway(s), which is not fully understood. In the endosomes, proteolytic removal of the N-terminal propeptide leads to the 48 kDa intermediate form, which is, however, active. Final processing yields the two domain mature enzyme, consisting of a heavy (34 kDa) and a light (14 kDa) chain that are non-covalently linked (Masson et al., 2010; Zaidi et al., 2008) . It has been suggested that processing of cathepsin D is mediated by cysteine proteases, and that cysteine cathepsins B and L are involved in the last processing step (Laurent-Matha et al., 2006) . In contrast, a previously reported partial autocatalytic processing was found to be an in vitro artifact (Masson et al., 2010; Zaidi et al., 2008) . Among other factors, which were reported to be involved in the activation of cathepsin D are GAGs (Beckman et al., 2009 ), prosaposin (Gopalakrishnan et al., 2004) and ceramide (Heinrich et al., 1999) .
Crystal structure of cathepsin D revealed a bilobal structure, highly similar to those of other pepsin-like aspartic proteases with the two active site Asp residues located in the active site cleft, each on one domain (Metcalf and Fusek, 1993) . The active site can accommodate up to 8 residues and the enzyme prefers hydrophobic residues, which was confirmed by a global proteomics study using mouse cathepsin D (Impens et al., 2010) .
No endogenous inhibitors of cathepsin D are known and the major factor in regulating mature cathepsin D activity seems to be the pH. The two active site Asp residues are namely prone to deprotonation suggesting that cathepsin D is predominantly active at pH below 5, such as found in lysosomes. However, cellular and in vivo data suggest that the enzyme can also be active at higher pH, which can be at least partially attributed to its abundance.
Apoptosis
Apoptosis is one of the major forms of programmed cell death, which also plays a major role in neuronal development and neurodegeneration. Apoptosis is highly conserved throughout evolution and driven by caspases, cysteine proteases with specificity towards the aspartate residue. There are two main pathways known to lead to caspase activation, namely the extrinsic or receptor's pathway and the intrinsic or mitochondrial pathway (Ashkenazi and Salvesen, 2014; Danial and Korsmeyer, 2004) (Fig. 3A) . In the extrinsic pathway, death ligands from the Tumor Necrosis Factor family bind to their cognate receptors (Fas-R, TNF-R1, TRAIL-R1/TRAIL-R2), thus leading to their oligomerization and binding to their adapter proteins, forming the death-inducing signaling complex (DISC), a scaffold for activation of the upstream caspases 8 and 10. On the other side, the intrinsic pathway is triggered by cellular stressors such as radiation, infectious agents, and/or drugs, leading to activation of the proapoptotic BH3-only members of the Bcl-2 family. Blockage of antiapoptotic Bcl-2 proteins would favor either Bax and/or Bak oligomerization and activation or the activated Bax and Bak would promote mitochondrial membrane permeabilization and the release of proapoptogenic factors such as cytochrome c. The latter would bind to Apaf-1, resulting in oligomerization and formation of apoptosome, which in turn serves as a scaffold for caspase-9 activation. A cross-talk between the extrinsic and intrinsic pathway was reported in the so called type II cells where the activated caspase 8 cleaves the proapoptotic BH3-only protein Bid, which subsequently triggers the intrinsic pathway.
In the last decade, major advances were seen regarding the involvement of other proteases (and organelles) in apoptosis. In particular, the involvement of lysosomal cathepsins was described in various cellular systems and it mainly proceeds through the lysosomal membrane permeabilization (Boya and Kroemer, 2008; Groth-Pedersen and Jäättelä, 2013; Johansson et al., 2010; Repnik et al., 2014; Stoka et al., 2007) . However, other mechanisms might include lysosomal translocation, as reported for cathepsin D during ageing (Sato et al., 2006) and changes in cathepsin expression upon cell death induction (Deiss et al., 1996) .
However, the function of the cathepsins in caspase-dependent apoptosis appears to be marginal and likely limited to assistance Fig. 3 . Involvement of lysosomal cathepsins in apoptosis (A) and autophagy (B). (A) During aging or upon induction of apoptosis by an intracellular stimuli i.e. radiation, infectious agents, and/or drugs, the lysosomal membrane becomes permeable (−·−·−), resulting in leakage of lysosomal cathepsins into the cytosol. In the cytosol, their activity is regulated by stefin B, a protein inhibitor member of type-1 cystatin's subfamily. When this regulation fails, cytosolic cathepsins proteolytically activate the Bid protein and degrade antiapoptotic Bcl-2 proteins, leading to Bax/Bak mediated mitochondrial membrane permeabilization (−·−·−) and release of cytochrome c. This leads to apoptosome formation and caspase-9 mediated activation of the executioner caspases −3 and −7, followed by apoptosis. Caspases-3, −7 and −9 are tightly regulated by the X-linked inhibitor of apoptosis (XIAP), preventing accidental triggering of the system. This pathway also at least partially contributes to neurodegeneration in the EPM1, when functional stefin B is lacking. The extrinsic (death receptor) pathway is triggered when a death ligand from the TNF family binds to a death receptor, thereby leading to formation of DISC and subsequent activation of the initiator caspases 8 and/or 10, followed by apoptosis, either directly or through activation of Bid and engagement of the mitochondrial pathway. Reactive oxygen species (ROS) are generated and released by mitochondria and/or lysosomes, acting as a positive feedback loop and enhancing the signaling response. (B) Three autophagy pathways are known, macroautophagy, microautophagy and chaperone-mediated autophagy (CMA) with lysosomes and cathepsins playing a crucial role in the degradation of the sequestered/delivered material in last step of autophagy. Lack of functional cathepsins D and F or mutations in their genes leading to their reduced activities, characteristic for CLN-10 and −13, seem to be linked to this pathway, although all the details are not clear.
in caspase activation through the engagement of the intrinsic apoptotic pathway, consistent with the major functions of the two protease families, namely, execution of apoptosis for caspases and intracellular protein turnover within lysosomes for cathepsins (Repnik et al., 2012; Turk and Stoka, 2007) . Anyhow, cathepsins, including cathepsins B, L and D, were also associated with the caspase-independent cell death (Aits and Jäättelä, 2013) , which might be of major importance also in the brain.
Autophagy
Autophagy participates both in the continuous turnover of intracellular proteins and organelles necessary to maintain cellular homeostasis, known as constitutive autophagy, and in the increased protein degradation in response to changes in the extracellular environment, known as inducible autophagy. Basal and inducible autophagy co-exist in all cells, although their prevalence varies depending on the cell type and cellular conditions (Cuervo, 2004; Mizushima et al., 2008; Orenstein and Cuervo, 2010) . Three main types of autophagy have been described in mammalian cells, macroautophagy, microautophagy and chaperone-mediated autophagy (CMA) (Cuervo, 2004; Orenstein and Cuervo, 2010) (Fig. 3B) . Although similar in many aspects, these autophagic pathways differ in the substrates degraded, the mechanism(s) by which the substrates are trafficking to the lysosome, and the stimuli mediating their activation (Orenstein and Cuervo, 2010) . However, all three pathways converge at the level of lysosomes, where degradation of engulfed or differently delivered organelles and biomolecules occur. Any defects in lysosomal machinery can thus lead to various diseases, including neurodegenerative and ageing-related diseases, as a result of protein misprocessing and accumulation.
Lysosomal enzymes in aging
Aging is a natural process characterized by a progressive loss of physiological integrity, leading to impaired function and increased vulnerability to death. Recently, nine hallmarks of aging, including genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient-sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication, were proposed (López-Otín et al., 2013) . Moreover, failure of homeostasis during aging is also due to the impaired function of one of the major cellular proteolytic mechanisms mediated by the lysosome (Cuervo and Dice, 1998, 2000) .
The endosomal-lysosomal system of neurons implicates the cathepsins as proteases capable of initiating, as well as executing, cell death programs during aging and in certain pathologic states (Nixon et al., 2000) . Among the cathepsins, especially cathepsins B, L and D were most often mentioned.
Already early studies using lysosomotropic drugs such as chloroquine or the broad spectrum cysteine cathepsin inhibitor leupeptin demonstrated that their injection into the brain of young rats resulted in morphological features only seen in aged brain, such as accumulation of lipofuscin and decline in dopamine receptors, suggesting that lysosomal cysteine cathepsins are likely involved (Ivy et al., 1989 (Ivy et al., , 1984 Nunomura and Miyagishi, 1993) . Soon after, Nakanishi et al. (Nakanishi et al., 1994) demonstrated that the activity, but not the protein levels, of cathepsin L were strikingly decreased in all the brain tissues of aged rats, suggesting the occurrence of a catalytically inactive form of cathepsin L in these tissues, possibly resulting from pH alterations in the lysosome due to extreme susceptibility of cathepsin L to increased pH (see above). The same study further demonstrated that the activity of cathepsin B remained relatively constant in brain also in aged animals, an exception being the striatum, where the activity was found to increase with age (Nakanishi et al., 1994) . It was further shown that inhibition of cathepsins B and L resulted in a proliferation of lysosomes and the formation of meganeurites in hippocampus, suggesting that meganeurite generation could serve to store catabolic organelles. However, separation of meganeurites from the parent cell was suggested to eventually result in axotomy (Bednarski et al., 1997) . These results lead the authors to propose that inhibition of cathepsin L in cultured slices could trigger a largely accelerated gerontological sequence, a process that may resemble aging (Bednarski et al., 1997) . Also other studies confirmed the findings that cathepsin B levels and activity were less affected during brain aging, although reports are somewhat conflicting. Porta et al. (1995) thus showed histochemically that cathepsin B levels remained unchanged in the brain from 14 to 24 months. However, the authors found that the activity of cathepsin B in brain homogenates was essentially unchanged during development (5-14 months), but significantly decreased from 14 to 24 months. Since the amount of accumulated lipofuscin increased linearly during development and aging, this lead them to suggest that cathepsin B was not linked to lipofuscin increase, contrary to previous findings (Ivy et al., 1984) . Similarly, cathepsin B was detected immunologically in multiple neurons and single matter astrocytes (Bernstein et al., 1990) .
Another source of cathepsins in brain during aging are activated microglia (von Bernhardi et al., 2015) . Microglia is distributed in the central nervous system (CNS) and comprise up to 20% of the total glial cell population. Activated microglia was suggested to be involved in neuroinflammation that is accompanying numerous neurodegenerative disorders, including Alzheimer's disease. The alteration of cathepsin expression during brain aging was suggested as a possible mechanism underlying the priming of microglia in the brain aging already some time ago (Nakanishi, 2003; Nakanishi and Wu, 2009 ). One such example is cathepsin B, which was suggested to be involved in NALP3 inflammasomemediated generation of interleukin 1-␤ as a response to A␤ (Halle et al., 2008) . Another microglia-secreted cathepsin is cathepsin S, which was found to be upregulated in aging and inflammatory processes of the CNS of mice (Wendt et al., 2008) . Moreover, it was reported that cortical microglia contain an intrinsic molecular clock and exhibit the circadian expression of cathepsin S. The latter was found to be critical for diurnal variations in the synaptic strength of the cortical neurons via the proteolytic modification of the perisynaptic environment. Genetic ablation of cathepsin S in mice was namely found to induce hyperlocomotor activity due to failure to reduce the synaptic strength during sleep, a step that is required for the acquisition of novel information after waking, thereby linking cathepsin S with sleeping disorders . In addition, cathepsin X, which is normally expressed by immune cells (Kos et al., 2005) , was found to be expressed in microglia and other parts of brain, and was found to be upregulated during aging and in some models of neurodegenerative disorders linked with neuroinflammation (Wendt et al., 2007) . Furthermore, such microglial cathepsin X was found to be involved in regulation of the brain function via processing of gamma enolase that may be important even for Alzheimer disease (Hafner et al., 2013) . Another cysteine cathepsin found to be associated with the brain function is cathepsin C (Koike et al., 2013) , which was found to be involved in normal neuronal function in certain brain regions, and to participate in inflammatory processes accompanying pathogenesis in the CNS.
In addition to cysteine cathepsins, several studies showed agedependent changes in cathepsin D expression and/or activity in human (Banay-Schwartz et al., 1992; Dorn et al., 1986) and rat brain tissue (Kenessey et al., 1989; Matus and Green, 1987; Nakamura et al., 1989a,b; Nakanishi et al., 1994; Snyder et al., 1985; Snyder and Whitaker, 1983) . In an early study in Wistar rats, the activity of cathepsin D was significantly increased with aging in cerebrum, hippocampus, pons and cerebellum (Nakamura et al., 1989a) . A more detailed study about the distribution of cathepsin D activity in 50 separate areas of the central nervous system of adult and aged humans showed that the change in the enzyme's activity was less pronounced with age in the human brain as compared with the rat brain (Banay-Schwartz et al., 1992) . Anyhow, some caution is needed in interpretation of these results as hemoglobin was used as a substrate. On this basis, a possible relationship between activation of cathepsin D and senile plaques formation in Alzheimer disease and aging was suggested (Haas and Sparks, 1996) .
In contrast, another aspartic protease, cathepsin E, was barely detectable in all the brain tissues of young adult rats (Nakanishi et al., 1994) . Moreover, in aged rats, where the cathepsin D levels in all of the brain tissues examined were higher than in young rats, cathepsin E levels were markedly increased only in the cerebral cortex and neostriatum of aged rats, but not in the other tissues (Nakanishi et al., 1994) . Furthermore, increased expression of cathepsins E and D in neurons of the aged rat brain and their colocalization with lipofuscin suggested changes in the endosomal/lysosomal proteolytic system possibly linked to lipofuscinogenesis and altered intracellular APP metabolism (Nakanishi et al., 1997) , in agreement with earlier studies (Ivy et al., 1984) . In addition, changes in the cathepsin D expression during postnatal development of rat CNS suggested that this protease may be involved in myelination (Snyder and Whitaker, 1983) . Moreover, in human tissue, cathepsin D was found to be present not only in multiple neurons, but also in some glial cells with increasing levels during neuroontogenesis (Dorn et al., 1986) . Regionally selective changes in brain lysosomes were observed in the transition from young adulthood to middle age in rats (Bi et al., 2000) . Pronounced age-related changes that involved primarily translocation of cathepsin D in neurons from lysosomes to cytosolic granules, were observed also in rat cerebral cortex in more than 35% of cells. Cathepsin B changes were much less pronounced, suggesting that these enzymes may be regulated differently and that they may play specific roles in the aging of the brain. Especially translocation of cathepsin D from the lysosomal system into the cytosol in the aged brain was suggested to play an important role in age-related cell death (Jung et al., 1999) . Early on, such cathepsin D release was suggested to be due to the lysosomal instability (Nakamura et al., 1989b) , however, it was shown later that cathepsin D translocation into the cytosol during aging was not accompanied by lysosomal membrane permeabilization. Furthermore, such cytosolic cathepsin D, was proposed as a biomarker of aging (Sato et al., 2006) .
There are also some reports about the molecular targets of cathepsins in the neuronal system, which are likely the consequence of the increased expression and/or translocation of cathepsin D. The enzyme was thus shown to degrade brain microtubule-associated proteins MAP-1 and MAP-2 (Leterrier and Eyer, 1992; Matus and Green, 1987) and, possibly, tubulin (Banay-Schwartz et al., 1983) , in an age-dependent fashion (BanaySchwartz et al., 1983; Leterrier and Eyer, 1992; Matus and Green, 1987) . Changes in the brain protease activity further suggest that an increase in enzyme activity observed previously during aging may also include changes in the enzyme specificity and/or susceptibility of the endogenous substrates for proteolysis (Benuck et al., 1996) . Another target of cathepsin D was the cytosolic tau protein in hippocampus. However, the process is more complex, and was found to be preceded by suppression of the cathepsin B and L activities. The selective suppression of cathepsin L was found to be accompanied by elevations in the lysosomal pH and proteolysis of tau protein. On this basis it was suggested that pH shifts initiate a sequence of events, which starts with inactivation of cathepsin L that is followed by induction of cathepsin D activity and aberrant tau proteolysis, and may have an important role in brain ageing (Bednarski and Lynch, 1996) .
Lysosomal cathepsins in neurodegeneration
Neuronal ceroid lipofuscinosis
The neuronal ceroid lipofuscinosis (NCLs) represents a special group within the inherited lysosomal storage disorders. Most human NCLs show an autosomal recessive mode of inheritance, and may have variable ages of onset such as congenital, infantile, late infantile, juvenile, adult or even late adult onset according to the severity of mutation (Anderson et al., 2013; Cárcel-Trullols et al., 2015; Haltia and Goebel, 2013) . The clinical features of most childhood forms include mental and motor deterioration, epileptic seizures, progressive loss of vision and premature death, whereas the rarer adult-onset forms are dominated by dementia (Anderson et al., 2013; Haltia and Goebel, 2013; Wisniewski et al., 2001) . Over 360 NCL-causing mutations are known, with over 90 novel disease-causing mutations reported (Kousi et al., 2012) . Most of the NCL-related genes encode soluble and transmembrane proteins, which localize to the endoplasmic reticulum or to the endosomal/lysosomal compartment and directly or indirectly regulate lysosomal function (Cárcel-Trullols et al., 2015; Kollmann et al., 2013) . However, three of the NCL proteins are lysosomal proteases, namely the serine protease tripeptidyl-peptidase 1 (TPP1, CLN2) and cathepsins D (CTSD, CLN10) and F (CTSF, CLN13).
Neuronal ceroid lipofuscinosis-10 (CLN10)
First indications that cathepsin D is linked with a fatal congenital form of NCL came from mouse studies (Table 1) . Cathepsin D deficient mice namely died early after birth (around day 26 postnatal) with a large number of autofluorescent lysosome-like structures in most of the neurons after day 23 (Koike et al., 2000) . Massive neuronal cell death was found to involve autophagy and caspaseindependent cell death Shacka et al., 2007) . Further studies demonstrated that spontaneous mutations in the cathepsin D gene in sheep and dogs also resulted in NCL (Awano et al., 2006; Tyynelä et al., 2000) . Finally, studies in human patients confirmed that mutations in the cathepsin D gene are indeed responsible for the most severe congenital form of NCL (Siintola et al., 2006; Steinfeld et al., 2006) . Today it is known that mutations in the human cathepsin D gene cause neuronal ceroid lipofuscinosis with congenital, late infantile or juvenile onset (Haltia and Goebel, 2013; Kollmann et al., 2013) .
To date, thirteen mutations in the cathepsin D gene were reported (Mole, 2015) . These mutations affect exons 3, 4, 5, 6, 7, 9 and introns 3 and 6 (Fritchie et al., 2009; Hersheson et al., 2014; Kousi et al., 2012; Siintola et al., 2006; Steinfeld et al., 2006) . The mutations identified were missense, nonsense, deletion, splice defect and/or sequence variation and some of them resulted in a change in the protein (Fritchie et al., 2009; Siintola et al., 2006; Steinfeld et al., 2006) . The sequence variation p. (Gly282Arg) might have a benign effect, whereas functional effects of the nonsense mutation p. (Tyr255*) and a deletion mutant p. (Lys331del) are still unknown (Mole, 2015; Siintola et al., 2006) . On the other side, missense mutations lead to p. (Ser100Phe) Arg399His) with predicted severe functional defects in the cathepsin D (Fritchie et al., 2009; Hersheson et al., 2014; Mole, 2015; Steinfeld et al., 2006) .
Although the phenotype of cathepsin B/L double deficient mice largely resembled that of cathepsin D-deficient animals (Table 1) and replace was even suggested to be a suitable model for studying NCL (Felbor et al., 2002; Koike et al., 2005) , no human patient with dysfunctional cathepsins B and L was identified so far. One reason is probably that such simultaneous double mutations leading to a major or even complete dysfunction of two different genes are much rarer, and the second that such human disease may be even more fatal. Interestingly, introduction of human cathepsin L into the double cathepsin B/L mouse knockout rescued the fatal phenotype, confirming that functional ablation of both cathepsins simultaneously is required for disease onset, as well as a major functional conservation of the enzymes across species (Sevenich et al., 2006) .
Very recently, using conditional knockout of cathepsin D in the cells of neuroectoderm, such as neurons and astroglia, but not microglia, demonstrated that this type of NCL is initiated by cells of neuroectodermal origin, thereby resolving a long lasting enigma (Ketscher et al., 2016) . Furthermore, such conditional cathepsin knock-out mice may provide further insight in the cell-type specific physiological and pathological roles of cathepsins in the brain in general, and not only in NCL. 6.1.2. Neuronal ceroid lipofuscinosis-13 (CLN13) First hints that cathepsin F is involved in NCL-like neurodegenerative disorders came from studies on cathepsin F-deficient mice (Table 1) , which developed neurological disease with onset at 12-16 months and died prematurely. Moreover, mice were also found to accumulate autofluorescent material in CNS (Tang et al., 2006) . It is now clear that mutations in the cathepsin F gene cause the adult-onset neuronal ceroid lipofuscinosis − Type B Kufs disease (Haltia and Goebel, 2013; Kollmann et al., 2013; Smith et al., 2013) .
Genome-wide linkage mapping of two families with recessive Type B Kufs disease and exome sequencing identified homozygous and heterozygous missense mutations in the cathepsin F gene within a single region on chromosome 11 (Smith et al., 2013) . To date, six rare or novel variants were detected and multiple lines of evidence suggest that cathepsin F variants are indeed pathogenic mutations due to the splice site, frameshift or missense mutation affecting exons 1, 5, 7, 12 and 13 (Fabio et al., 2014; Smith et al., 2013) . The nucleotide change c.954delC leads to a frameshift and subsequent nonsense mutation with a protein change p. (Ser319Leufs*27) resulting in the C-terminus deletion (Mole, 2015; Smith et al., 2013) . Missense mutations lead to p. (Tyr231Cys), p. (Gln321Arg), p. (Gly458Ala), p. (Ser480Leu), with predicted probably damaging functional effects (Mole, 2015; Smith et al., 2013) . More recently, the nucleotide change c.213 + 1G > C in cathepsin F was found to affect correct splicing, removing exon 1, and predicted a truncated N-terminus of cathepsin F (Fabio et al., 2014) . In addition, we showed that overexpression of N-terminally truncated forms of human cathepsin F in HEK 293T cells resulted in accumulation of the enzyme in aggresome-like inclusions, exhibiting p62-positive immunoreactivity that were colocalized with the autophagy marker LC3B, thereby suggesting their clearance via the autophagy-lysosomal pathway (Jerič et al., 2013 ).
Alzheimer's disease
Alzheimer's disease (AD) is the most prevalent neurodegenerative disease and cause of dementia in the elderly. It is characterized by an accumulation of misfolded proteins, inflammatory changes and oxidative damage. This results in region-specific loss of synaptic contacts and neuronal cell death. The exact mechanisms of neuronal degeneration in sporadic AD, which accounts for vast majority of cases, are still unknown (Querfurth and LaFerla, 2010; Yu et al., 2014) . One of the major proteins that was found to associate with Alzheimer's disease by forming amyloid plaques in the brain or toxic fragments, which also contribute to the disease progression, is amyloid precursor protein (APP). Since APP is a subject of extensive proteolytic processing, it is not surprising that lysosomal proteases have been associated with Alzheimer's disease for a long time, when they were first found to be associated with the senile plaques in patients (Cataldo and Nixon, 1990) . However, when cathepsin D-deficient primary hippocampal neurons were tested for their ability to process APP, no major differences were seen when compared with wild-type neurons, ruling out cathepsin D as the major APP-processing enzyme . Moreover, after the discovery of BACE and ␥-secretase, none of the cathepsins was in the mainstream anymore (Querfurth and LaFerla, 2010) . Despite major investments into the removal of A␤ either by secretase inhibition or by other means, the outcome was no viable therapy so far, although some advanced clinical studies are still not finished and their results eagerly awaited. Recently, the therapeutic focus moved away from A␤ to Tau (Giacobini and Gold, 2013) , and neuroinflammation was shown to be an important part of AD, giving some more space also to lysosomal proteases. Along this line is also a revived interest in cathepsin D, although more focused on diagnostics, including imaging (Snir et al., 2015) . It is now clear that lysosomal proteases could only contribute to AD by proteolytic processing or via autophagy, which plays a major role in the disease through clearance of accumulated material, including A␤ (Nixon, 2013; Nixon and Cataldo, 2006) . The story with cysteine cathepsins is, however, more complex. Some studies suggested that cathepsin B is in vivo very efficient in degrading A␤ (Mueller-Steiner et al., 2006) , which was even potentiated by genetic ablation of cystatin C, thereby promoting the so called "cathepsin B-cystatin C axis", which suggested a neuroprotective role of cathepsin B in AD (Sun et al., 2008) . However, at about the same time it was demonstrated that cystatin C may directly interact with A␤. Furthermore, it's in vivo overexpression in a transgenic AD model demonstrated a substantial reduction in A␤ burden, thereby giving another view, albeit not pointing in the same direction (Mi et al., 2007) . In addition, contrary to some of the above results, cathepsin B inhibition in vivo was shown to improve memory and reduce A␤ in transgenic Alzheimer's disease mice expressing the wild-type APP, whereas they had no effect on the mice overexpressing the Swedish mutant APP, which lead the authors to suggest that BACE is not the best protease to degrade wild-type APP (Hook et al., 2011 (Hook et al., , 2008 . Cathepsin B was therefore also suggested as a potential target in AD (Hook et al., 2014) , but further studies will be required to clarify these discrepancies. Anyhow, cathepsin B has been also suggested to be a key enzyme for the mature interleukin-1␤ production by activated microglia, which is responsible for neuroinflammation in AD that may also explain the beneficial effect of cathepsin B inhibitors in mice. In addition, legumain, which was also found to be activated in the aging brain and in AD brain , was found to be involved in Tau phosporylation through inactivation of a protein phosphatase 2 inhibitor I2 (Iqbal et al., 2016) as well as in degradation of Tau, thereby abolishing its microtubule assembly function and inducing its aggregation that lead to neurodegeneration ).
Parkinson's disease
Parkinson's disease is the most common serious locomotive disorder in the world, affecting about 1% of adults older than 60 years.
The disease is attributed to selective loss of neurons in the substantia nigra, and its cause is enigmatic in most individuals (Samii et al., 2004) . One of the major proteins associated with the pathology of Parkinson's disease is ␣-synuclein. Cathepsin D was the first lysosomal protease found to protect against ␣-synuclein aggregation and toxicity in mouse models (Cullen et al., 2009; Qiao et al., 2008; Sevlever et al., 2008) . In vitro experiments have demonstrated that cathepsin D degrades ␣-synuclein very efficiently and that limited proteolysis resulted in generation of C-terminally truncated species known to contribute to pathogenesis of the disease. Moreover, using cathepsin D-deficient lysosomes the authors confirmed these findings, suggesting that cathepsin D is indeed the main lysosomal enzyme involved in ␣-synuclein degradation (Sevlever et al., 2008) . In agreement, overexpressed cathepsin D was found to effectively degrade ␣-synuclein in dopaminergic cells, whereas cathepsin D-deficient mice accumulated insoluble ␣-synuclein in the brain, thereby facilitating ␣-synuclein toxicity (Cullen et al., 2009) . Similar results, i.e. ␣-synuclein accumulation in cathepsin D-deficient animals and neuroprotection against ␣-synuclein toxicity in cathepsin D-overexpressing neuroglioma cells, were also observed by Qiao et al. (Qiao et al., 2008) . Very recently, it was demonstrated in a cellular model that even partial loss of cathepsin D activity due to heterozygous mutation was sufficient to reduce lysosomal function, and result in subsequent ␣-synuclein aggregation (Bae et al., 2015) . Similarly, pharmacological inhibition of cathepsin D or overexpression of a catalytically inactive cathepsin D variant were found to increase not only endogenous ␣-synuclein levels, but also cathepsin B activity in SH-SY5Y cells. However, this increased cathepsin B activity could not compensate for the loss of cathepsin D, arguing for a critical role of cathepsin D in this model (Crabtree et al., 2014) . In contrast, using lysosomal extracts and mass spectrometry analysis, cathepsin D was recently found only to generate the C-terminal ␣-synuclein fragments, whereas the majority of ␣-synuclein degradation was associated with cathepsin L, and to a lesser extent with cathepsin B. However, the activity of cathepsin D on ␣-synuclein was largely increased in the presence of anionic phospholipids, reaching cathepsin B levels (McGlinchey and Lee, 2015) . Interestingly, in a cellular study cathepsin B, but not cathepsin D, was found to be the major enzyme in fibrilinduced formation of intracellular aggregates of ␣-synuclein, using the cathepsin B selective inhibitor CA-074Me and pepstatin as a cathepsin D inhibitor. Similar results were obtained by cathepsin B knockdown (Tsujimura et al., 2015) . Further studies are therefore needed to resolve this discrepancy.
Polyglutamine-related disorders
An expansion of polyglutamine (polyQ) sequences is known to lead to neurodegeneration as seen in e.g. Huntington disease and spinocerebellar ataxia type 3, (Zoghbi and Orr, 2000) . The resulting aggregation-prone mutant proteins accumulate in cells as intracellular protein inclusions and cause neuronal disease through toxic gain-of-function mechanisms (Rubinsztein, 2006) . Recently, using cathepsin-deficient cells and pharmacological inhibitors, cathepsins L and X (Z) were found as the critical lysosomal proteases capable of degrading polyQ proteins and peptides, but not other aggregation-prone proteins, suggesting that they may have an important role in protection against toxic polyQ protein aggregates (Bhutani et al., 2012) .
Huntington disease
Huntington's Disease (HD) is a progressive, fatal, autosomal dominant neurodegenerative disorder characterized by motor, cognitive, behavioral, and psychological dysfunction (Borgs et al., 2012; Paulson and Albin, 2011) . The pathological mechanisms of HD are not fully understood, but increasing evidences suggest that in addition to the gain of toxic properties, loss of wild-type huntingtin function also contributes to pathogenesis (Borgs et al., 2012) .
Multiple studies suggested that an important role in disease progression has proteases including caspases, calpains, proteasome and matrix metalloproteases, which were all found to be involved in N-terminal proteolysis of huntingtin (Miller et al., 2010; Qin and Gu, 2004) . In addition, the autophagy-lysosomal pathway was also found to regulate processing of the N-terminal huntingtin fragments (Kegel et al., 2000; Liang et al., 2011; Qin et al., 2003; Ravikumar et al., 2002) , thereby involving cathepsin D (Kegel et al., 2000; Kim et al., 2006; Liang et al., 2011; Qin et al., 2003) and cysteine cathepsins B, L and/or X (Z) (Kim et al., 2006; Liang et al., 2011; Ratovitski et al., 2011) .
Already early studies demonstrated that huntingtin accumulated in vacuoles that resembled endolysosomal organelles of dying HD neurons (Sapp et al., 1997) . When these huntingtin-enriched cytoplasmic vacuoles were further investigated in vitro, they were found to contain cathepsin D in levels proportional to the length of the polyQ region in huntingtin. Moreover, these vacuoles had all the ultrastructural features of autophagosomes, suggesting involvement of autophagy (Kegel et al., 2000) . Kim et al. (2006) have shown some time later that in a similar cellular model, i.e. clonal striatal cells, not only cathepsin D, but also cathepsins B and L were involved in the N-terminal processing of mutant huntingtin. However, although the cathepsins were found to degrade mutant huntingtin, the authors did not exclude an alternative explanation, i.e. formation of stable N-terminal fragments with toxic function. Similar results were also found later when overexpression of cathepsins B and D in both HEK and primary neurons protected cells against mutant huntingtin through enhanced autophagy (Liang et al., 2011 ).
Amyotrophic lateral sclerosis
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease characterized by loss of motor neurons, which results in weakness and atrophy of voluntary skeletal muscles, leading to death of patients within 3-5 years after diagnose. Vast majority of ALS cases (∼85%) are classified as sporadic ALS with unknown aetiology, whereas the remaining 15% are familial with dominant inheritance. Among the latter, about one fifth are due to mutations in the superoxide dismutase (SOD1), which is often used in the animal models of the disease (Paez-Colasante et al., 2015) Studies in ALS model mice revealed expression and protein levels of the cathepsins B, L, S, X and D all increased in the spinal cord in ALS mice, generated by mutating the copper/zinc superoxide dismutase (SOD1) gene (Wendt et al., 2008; Wendt et al., 2007; Wootz et al., 2006) . However, in ALS patients only cathepsin B was found involved in the motor neuron degeneration, whereas cathepsins H, L and D were not significantly affected (Kikuchi et al., 2003) . More recently, a cDNA microarray analysis on postmortem spinal cord specimens of four sporadic ALS patients revealed major changes in the expression of mRNA in 60 genes including increase of cathepsins B and D (Offen et al., 2009) . Since the results were in good agreement with the results they obtained in the SOD1 transgenic mouse model, the authors further suggested that at least some of these genes may play a more specific role in the pathogenesis of ALS (Offen et al., 2009 ).
In addition, cystatin C exogenously added to cells exhibited a neuroprotective role, which partially included inhibition of cathepsin B, suggesting that targeting cystatin C in motor neurons may provide a novel therapeutic strategy for ALS (Watanabe et al., 2014) . In addition, in cells stably transfected with the SOD1 ALS mutant, stefin B was found upregulated (Ulbrich et al., 2014) , however, any relations with ALS require in vivo confirmation.
Involvement of endogenous cathepsin inhibitors in CNS diseases
In addition to lysosomal proteases, also mutations in the endogenous cathepsin inhibitors cystatin C and stefin B were found responsible for two of the CNS diseases, hereditary cystatin C amyloid angiopathy (Palsdottir et al., 2006) and progressive myoclonus epilepsy 1 or the Unverricht-Lundborg disease (EPM1) (Lalioti et al., 2003) .
Hereditary cystatin C amyloid angiopathy
Hereditary cystatin C amyloid angiopathy is a fatal autosomal dominant genetic disorder originating from Iceland, which is characterized by deposition of a cystatin C mutant, L68Q, in the brain, predominantly in brain arteries and arterioles resulting in a series of strokes and hemorrhagic brain damage finally leading to premature death with an average life span of around 30 years (Ghiso et al., 1986; Levy et al., 2006; Palsdottir et al., 2006) . This naturally occurring mutant has a much higher tendency to aggregate than the wild-type protein, thereby forming amyloids (Abrahamson and Grubb, 1994) . A sporadic form of the disease was also identified in a Croatian patient. However, the disease is not linked to cathepsin inhibition, but rather belongs to other amyloid diseases, such as Alzheimer's disease.
EPM1
Mutations in the gene for Stefin B (CSTB), the major intracellular endogenous cysteine cathepsin inhibitor, were found responsible for a rare neurodegenerative form of progressive myoclonus epilepsy of the Unverricht-Lundborg type (Lalioti et al., 1997; Pennacchio et al., 1996) , which is most prevalent in Finland and some Mediterranean countries (North Africa), and is characterized by seizures, ataxia and a major loss of the Purkinje cells in the cerebellum. The majority of patients carry a mutation involving a dodecamer repeat expansion in the promoter region, which results in the lack of protein expression (Lalioti et al., 1997) . Mice with ablated CSTB gene developed similar symptoms as found in patients, including a major loss of Purkinje cell in the cerebellum (Pennacchio et al., 1998) . Neuronal cell death, but not ataxia, was found to be associated with increased cathepsin B activity, as demonstrated by introducing human cathepsin B gene into the CSTB-deficient mice (Houseweart et al., 2003a) , suggesting that the inhibitory activity of stefin B is at least partially responsible for the disease development. However, although cathepsin apoptosis is known to progress through cleavage of Bid, simultaneous removal of Bid and stefin B did not rescue from neuronal cell death (Houseweart et al., 2003b ). An increase in cathepsin B activity was also seen in the EPM1 patients (Rinne et al., 2002) , and in primary cerebellar granule cultures of CSTB KO mice (Lehtinen et al., 2009 ). In addition, several point mutations were described in the CSTB gene, which are likely affecting protein stability and/or its inhibitory function (Lalioti et al., 2003) . However, stefin B was found to interact with a number of proteins involved in cytoskeletal organization (Di Giaimo et al., 2002) , suggesting that the loss of cathepsin inhibition is not the only reason for the disease progression, in agreement with mouse studies (Houseweart et al., 2003a) . In line with this idea, stefin B was found to protect neurons (Lehtinen et al., 2009) , and also tumors (Butinar et al., 2014) from oxidative stress. Moreover, a strong nuclear signal and a diffuse representation in the cytoplasm was reported for an EPM1 patient with a p.G50E missense mutation (Joensuu et al., 2007) , which may have also some functional consequences, as stefin B was already observed in the nucleus, where it was found to interact with histones and cathepsin L, and delayed apoptosis independently of cathepsin inhibition (Čeru et al., 2010; Sun et al., 2012) . Few of the mutations were also reported to affect protein stability and some of them were found to form amyloid fibrils in vitro. Moreover, when overexpressed in cells several stefin B mutants, G4R, R68X, G50E and Q71P, also formed intracellular aggregates, which were suggested to be potentially cleared by autophagy (Čeru et al., 2010; Polajnar et al., 2014) . Such stefin B polymerization and aggregate formation has been related to the redox environment (Cipollini et al., 2008) and on the binding of copper ions which may impair protein aggregation (Žerovnik et al., 2006) . In addition, a novel stefin B mutation c.66GNA was reported recently (Duarte et al., 2015) . The distribution of protein detected in the patient cells exhibited nuclear location whereas the lysosomes show a slightly different distribution. Since the above mentioned mutation has a milder effect, leading to a small amount of normal transcript, in addition to the abnormal transcript (Pinto et al., 2012) , the authors confirmed that the normal form is likely to ensure partial minimal function, in agreement with the slower progressive form of disease presented by the patient. The putative aberrant protein resulting from the abnormal transcript (c. 66GNA) might be more prone to aggregate formation and lead to a toxic gain of function (Duarte et al., 2015) , However, protein aggregation was not seen in any EPM-1 patient as yet, and overexpression of a protein in cells may give misleading results, especially since the disease is largely accompanied with decreased levels of stefin B. Therefore, such findings have to be interpreted with care.
Small cathepsin inhibitors as a point for therapeutic intervention
The small synthetic and natural inhibitors provide an excellent tool for targeting proteases, including cathepsins. The first such example was the cathepsin D inhibitor pepstatin (Umezawa, 1982) , which is still the most widely used inhibitor of aspartic proteases in the laboratory praxis. Similar is true for the epoxysuccinyl inhibitor E64, an irreversible broad-spectrum inhibitor of cysteine cathepsins (Barrett et al., 1982) . On this basis, the first selective inhibitors of cathepsin B such as CA030, CA074 and their analogs were developed Towatari et al., 1991) , followed by related inhibitors of cathepsins K, L and S Tsuge et al., 1999) . Development of cysteine cathepsin inhibitors largely expanded with improved understanding of their biological roles and currently various primarily nitrile type inhibitors are in preclinical or clinical investigations (Deaton and Kumar, 2004; Frizler et al., 2010; Turk, 2006) . However, although cathepsin K inhibitors showed excellent results in a Phase III clinical study for osteoporosis treatment, cathepsin S inhibitors entered clinical trials for psoriasis, neuropathic pain and Crohn's disease, and several of them are in preclinical studies for inhibition of cathepsins B, L and S in cancer (Fonović and Turk, 2014; Olson and Joyce, 2015) , atherosclerosis, and some other diseases, essentially none of them advanced for the treatment of CNS diseases, since Virobay Inc. apparently discontinued development of a cathepsin S inhibitor for treatment of Alzheimer disease. Most of them are still at a proof of principle level such as the cathepsin B inhibitors for the treatment of Alzheimer disease. Similarly, no cathepsin D inhibitors are seriously considered for the treatment of CNS diseases, and cathepsin D was only shown to be a potential off-target of some early BACE inhibitors.
Conclusions
Cathepsins mostly participate in neuronal processes through processing of or clearance of proteins, the latter largely involving autophagy. In addition, cathepsins were also found to be involved in neuronal cell death, which was often caspase-independent. While mutations in cathepsins D and F were found to be critical for the development of CLS, active treatment of cathepsins by pharmacological inhibition may not be the most viable option, as they were not found to be critical targets in the CNS diseases. In addition, also mutations in two endogenous cathepsin inhibitors, cystatin C and stefin B, were found to be critical for the development of two CNS diseases, although the lack of cathepsin inhibition does not appear to be the only reason for them.
